<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05037617</url>
  </required_header>
  <id_info>
    <org_study_id>REB21-0614</org_study_id>
    <nct_id>NCT05037617</nct_id>
  </id_info>
  <brief_title>The REDUCED-I Pilot Trial: REDucing the Utilization of CEsarean Sections With Induction</brief_title>
  <acronym>(REDUCED-I)</acronym>
  <official_title>The REDUCED-I Pilot Trial: REDucing the Utilization of CEsarean Sections With Induction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot project is a randomized controlled trial where induced patients receive an&#xD;
      intervention of oxytocin discontinuation once in the active stage of labor (≥6 cm dilation).&#xD;
      The intent is to reduce uterine hyperstimulation and fetal distress, therefore, lowering&#xD;
      cesarean sections (CS) in first time mothers at term (≥ 37 weeks), with a cephalic presenting&#xD;
      singleton fetus, without increasing maternal or neonatal morbidity. If REDUCE-I pilot trial&#xD;
      suggests a safe reduction in CS rates and patient satisfaction, application for a&#xD;
      multi-centre randomized controlled trial would follow.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot project is a randomized controlled trial of a proposed intervention to modify&#xD;
      management of labor inductions once in the active first stage of labor. The intervention will&#xD;
      take place at Foothills Medical Centre (FMC). Randomization will be computer generated,&#xD;
      participants will be stratified by need for cervical ripening and randomization will be&#xD;
      blocked. Participants will be primiparous women 18 years old or older, at term (≥ 37 weeks)&#xD;
      with a cephalic presenting singelton fetus undergoing induction of labor with oxytocin. Once&#xD;
      patients are in the active first stage of labor, study medication will be initiated&#xD;
      (identical vials of oxytocin or saline prepared by the Alberta Health Services Research&#xD;
      Pharmacy). Treatment period will continue until delivery. If the frequency of contractions&#xD;
      are reduced to less than 2 in 10 minutes or there has been no change in dilation for 4 hours,&#xD;
      then oxytocin can be restarted.&#xD;
&#xD;
      Royal Alexandra Hospital in Edmonton will be used as a contemporaneous non-intervention&#xD;
      control site.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Once a patient is found to be &gt;=6 cm dilation, the patient will received a blinded vial of oxytocin or saline, which will be numbered according to the random allocation sequence created by the study statistician.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Once a patient is found to be ≥6 cm dilation, the study medication will be initiated. Pharmacy will make up identical vials of oxytocin or saline, which will be numbered according to the random allocation sequence created by the study statistician. Nurses will use the blinded vials for ongoing infusion. Patients and caregivers will be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Cesarean section in labor</measure>
    <time_frame>At Delivery</time_frame>
    <description>Rate of Cesarean section in labor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Uterine Hyperstimulation</measure>
    <time_frame>During labour, after &gt;=6 cm dilation</time_frame>
    <description>Occurrence of &gt;5 contractions in 10 minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of screened subjects who agree to enroll in the trial</measure>
    <time_frame>During screening of potential participants</time_frame>
    <description>Proportion of screened subjects who agree to enroll in the trial</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of perinatal death</measure>
    <time_frame>At delivery</time_frame>
    <description>Rate of perinatal death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of neonatal asphyxia</measure>
    <time_frame>At delivery</time_frame>
    <description>Neonatal asphyxia is defined as intrapartum stillbirth or neonatal death from asphyxia (Perinatal Society of Australia and New Zealand coding) or Neonatal Intensive Care Unit admission and at least two of: a. Apgar score of ≤5 at 10 minutes; b. Mechanical ventilation or chest compressions for resuscitation within 10 minutes; c. Cord pH &lt; 7.00 (venous or arterial), or arterial base excess ≥ 12 at birth. Rate of neonatal asphyxia for deliveries involving primiparous women in labor, at term (&gt;= 37 weeks), with a vertex presenting singleton fetus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of moderate or severe asphyxia (Sarnat) or meets criteria for therapeutic cooling</measure>
    <time_frame>At delivery</time_frame>
    <description>Rate of moderate or severe asphyxia (Sarnat) or meets criteria for therapeutic cooling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of neonatal sepsis or suspected sepsis</measure>
    <time_frame>At delivery</time_frame>
    <description>Rate of neonatal sepsis or suspected sepsis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of postpartum hemorrhage</measure>
    <time_frame>At delivery</time_frame>
    <description>Rate of postpartum hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of blood transfusion</measure>
    <time_frame>At delivery</time_frame>
    <description>Rate of blood transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of postpartum uterine artery/pelvic artery embolization</measure>
    <time_frame>Within 28 days of delivery</time_frame>
    <description>Rate of postpartum uterine artery/pelvic artery embolization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of postpartum hysterectomy</measure>
    <time_frame>Within 28 days of delivery</time_frame>
    <description>Rate of postpartum hysterectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of postpartum maternal intensive care unit (ICU) admission</measure>
    <time_frame>At delivery</time_frame>
    <description>Rate of postpartum maternal intensive care unit (ICU) admission</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Duration of oxytocin discontinuation</measure>
    <time_frame>During labour, after &gt;=6 cm dilation</time_frame>
    <description>Duration of oxytocin discontinuation</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of reintroduction of oxytocin infusion</measure>
    <time_frame>During labour, after &gt;=6 cm dilation</time_frame>
    <description>Rate of reintroduction of oxytocin infusion</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Induced; Birth</condition>
  <arm_group>
    <arm_group_label>Intervention site (Foothills Medical Centre): Continuation of Oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will receive a blinded vial of oxytocin once a patient is found to be &gt;= 6 cm dilated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention site (Foothills Medical Centre): Discontinuation of oxytocin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this arm will receive a blinded vial of saline solution once a patient is found to be &gt;= 6 cm dilated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Continuation or discontinuation of oxytocin during the active first stage of labor (≥6 cm dilation).</intervention_name>
    <description>At the intervention site (Foothills Medical Centre), for participants who consent to being part of the trial, once a patient is found to be &gt;= 6 cm dilation, the study medication will be initiated. Pharmacy will make up identical vials of oxytocin or saline, which will be numbered according to the random allocation sequence created by the study statistician.&#xD;
The intervention will be continued until delivery unless contractions decrease to less than 2 in 10 minutes or if no further cervical dilation is noted 4 hours after discontinuation.</description>
    <arm_group_label>Intervention site (Foothills Medical Centre): Continuation of Oxytocin</arm_group_label>
    <arm_group_label>Intervention site (Foothills Medical Centre): Discontinuation of oxytocin</arm_group_label>
    <other_name>oxytocin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  pregnant women undergoing induction of labor with oxytocin.&#xD;
&#xD;
          -  Primiparous&#xD;
&#xD;
          -  18 years old or older&#xD;
&#xD;
          -  at term (≥37 weeks)&#xD;
&#xD;
          -  cephalic presenting&#xD;
&#xD;
          -  singleton fetus&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multiple pregnancies&#xD;
&#xD;
          -  known fetal congenital or chromosomal anomalies&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen L Wood, MD, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephen L Wood, MD, FRCSC</last_name>
    <phone>403-944-1438</phone>
    <email>stephen.wood@ahs.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Janice Skiffington, MSc</last_name>
    <phone>403-944-8446</phone>
    <email>janice.skiffington@ahs.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Wood, MD</last_name>
      <phone>403-944-1438</phone>
      <email>slwood@ucalgary.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 19, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Calgary</investigator_affiliation>
    <investigator_full_name>Stephen Wood</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Obstetric Labor Complications</keyword>
  <keyword>Cesarean section</keyword>
  <keyword>Induced labour</keyword>
  <keyword>oxytocin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 15, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT05037617/Prot_SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

